Kezar Life Sciences Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kezar Life Sciences stock.
View analyst ratings for Kezar Life Sciences or view top-rated stocks.

Wall Street analysts have given Kezar Life Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kezar Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Kezar Life Sciences saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,680,000 shares, an increase of 43.6% from the January 28th total of 1,170,000 shares. Based on an average daily volume of 229,900 shares, the days-to-cover ratio is presently 7.3 days.
View Kezar Life Sciences' Short Interest.

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Kezar Life Sciences.

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04.
View Kezar Life Sciences' earnings history.

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KZR stock has increased by 46.1% and is now trading at $5.83.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1 year price objectives for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 157.3% from the stock's current price.
View analysts' price targets for Kezar Life Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Kezar Life Sciences include Akero Therapeutics (AKRO), Enanta Pharmaceuticals (ENTA), Trillium Therapeutics (TRIL), Avid Bioservices (CDMO), Radius Health (RDUS), ORIC Pharmaceuticals (ORIC), Repare Therapeutics (RPTX), Vanda Pharmaceuticals (VNDA), Vectura Group (VEGPF), Epizyme (EPZM), Syndax Pharmaceuticals (SNDX), Dynavax Technologies (DVAX), ZIOPHARM Oncology (ZIOP), Phibro Animal Health (PAHC) and MannKind (MNKD).
View all of KZR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.44%), Opaleye Management Inc. (1.53%), Candriam Luxembourg S.C.A. (1.26%), Alyeska Investment Group L.P. (1.26%), Alyeska Investment Group L.P. (1.26%) and Kennedy Capital Management Inc. (1.14%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends for Kezar Life Sciences.

KZR stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, CHI Advisors LLC, Victory Capital Management Inc., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., Northern Trust Corp, Virtus ETF Advisers LLC, and Alyeska Investment Group L.P..
View insider buying and selling activity for Kezar Life Sciences or view top insider-selling stocks.

KZR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, GSA Capital Partners LLP, Caas Capital Management LP, Opaleye Management Inc., Renaissance Technologies LLC, ProShare Advisors LLC, and State of Wisconsin Investment Board. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment, and Vassiliki Economides.
View insider buying and selling activity for Kezar Life Sciences or or view top insider-buying stocks.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KZR stock can currently be purchased for approximately $5.83.

Kezar Life Sciences has a market capitalization of $269.74 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

Kezar Life Sciences employs 40 workers across the globe.

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Kezar Life Sciences is headquartered at 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]